- Timo grimmer is in the team - All endpoints of the clinical trial were reached I firmly believe that the drug works and that the CEO has done a good job no matter how much he is criticized.

The drug shows it works as is!

we have a drug, even many drugs, good for so many indications, to become a giant pharma, we are about to get billions in revenues.

$AVXL The improvements in the drug arm cannot be lucky. .

Our drug has no side effects.

I'm looking forward to seeing the long term AD data on ANVS and have the feeling it's going to end up being the best in class AD treatment as well.

Do not listen to any FUD this drug is the real deal.

$AVXL amazing to see the actual benefits to people and their families of this “miracle drug” as they call it

$AVXL Dr. Perry said we have a legendary drug which actually reverses AD and is safe unlike Adulhelm.

Clearly the drug is working !

That’s a lot of money to invest multiple times on a promising treatment 🚀

This is the ONLY drug in HISTORY to improve cognition after 12 months.

$SAVA A safe drug that impacts both neurodegeneration and neuroinflammation is going to have potential treating other CNS diseases.

Proper stock and proper drug doesn't smell like a scam.

Deeply appreciative of the treatment that SAVA is working to deliver,

$SAVA this is going to be game changer and first drug to give some relief to AD patients … and will make $BIIB poison AD pills an obsolete

I’m holding long term because I truly believe this is the first effective Alz treatment to date.

$SAVA Data is good and the drug works.

As the company continues to bring new treatments to market, it is likely that Biocryst will continue to be a leader in the field of rare disease treatment, providing both patients and investors alike with a brighter future.

gets a drug approved and immediately rewards shareholders!!!

A great drug like Orladeyo and this is what we get in terms of stock performance. FAILURES

We have a revenue generating drug thats just achieved 105% YoY growth.

If you want a derisked, undervalued company with an approved potential blockbuster drug that can provide steady and incremental ROI year over year, plus the added bonus of pipeline drugs adding more value in future… this stock will be a keeper

BCX 9930 was a very promising and exciting drug and it probably is.

$BCRX 9 slides in the presentation about why its "hard" to design drugs lmfao. hilarious.

"We believe BCX10013 has the potential to be a best-in-class treatment option with an oral, once-daily profile,”

Brags how great drug discovery platform

$BCRX -- Takeda’s HAE Drug Takhzyro Enjoying Positive Uptake in Japan -- Good news for Orla I guess .